OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

April 13, 2026

RE: Product-Based Prior Authorization for Hereditary Angioedema (HAE) Medications Effective May 1, 2026

Effective May 1, 2026, OHCA will add HAE Medications to the Product Based Prior Authorization (PBPA) program.

Members currently utilizing HAE medications will be able to continue its use. New starts will be required to meet initial approval criteria in addition to any tier specific criteria. The tier charts for HAE Prophylaxis Products and HAE Treatment Products are provided below.

The specific prior authorization (PA) requirements for these products are located on the OHCA website at www.oklahoma.gov/ohca/pa in the "Cardiovascular" therapeutic category. Form PHARM-321 is used for HAE medication PA requests and can be found on the ohca website at www.oklahoma.gov/ohca/rxforms.

Hereditary Angioedema (HAE) Prophylaxis Products			
Tier-1	**Tier-2**	**Tier-3**	**Special PA**
Orladeyo® (berotralstat)	Cinryze® (C1 esterase inhibitor)	Takhzyro® (lanadelumab-flyo)	Andembry® (garadacimab-gxii)
	Haegarda® (C1 esterase inhibitor)		Dawnzera™ (donidalorsen)

Hereditary Angioedema (HAE) Treatment Products		
Tier-1	**Tier-2**	**Special PA**
Firazyr® (icatibant)	Berinert® (C1 esterase inhibitor)	Ekterly® (sebetralstat)
	Sajazir™ (icatibant)	Kalbitor® (ecallantide)
		Ruconest® (C1 esterase inhibitor)

Thank you for the services you provide to Oklahomans insured by SoonerCare!